Psychedelics have the ability to completely transform the mental health care sector as we know it. Mydecine was formed with the goal of discovering, analyzing, and bringing psychedelic and functional chemicals to worldwide markets to aid in the treatment of mental health and addiction. Our clinical trials are mostly focused on psychedelic-assisted psychotherapy for PTSD and nicotine addiction.
We will begin a phase 2b clinical investigation in collaboration with Johns Hopkins University, which will be supervised by Dr. Matthew Johnson. Dr. Johnson is a Psychiatry and Behavioral Sciences professor at Johns Hopkins. He is one of the world's most published scientists on the human impacts of psychedelics, and his work in the behavioral economics of drug use, addiction, and risk behavior is seminal. The proposed research compares MYCO-001 to a structured smoking cessation therapy program in nicotine-dependent adults.
Mydecine will deliver MYCO-001 for Dr. Matthew Johnson's multi-site smoking cessation experiment at Johns Hopkins, NYU, and UAB. This is the first time in over 50 years that the U.S. government has supported a psychedelic medicines study. Supplying our main drug candidate for this study demonstrates Mydecine's leadership in the growing psychedelic-assisted psychotherapy business.
Mydecine is developing drug family of microdose psilocybin analogs to provide patients with a better option to SSRI drugs.
Mydecine is developing its MYCO-006 drug family of molecules to make MDMA therapy more commercially viable. The MYCO-006 compounds share the same therapeutic effect as Gen-1 MDMA, and animal research has revealed a successful shorter half-life duration. MYCO-006 compounds are projected to last one-third the time as MDMA, lasting around one to two hours vs. the conventional six to eight-hour course of Gen-1 MDMA, with a four-fold onset increase.